/predictions/drug-responsePredict Drug Response
Predict how a compound will affect a gene/target and verify against experimental databases.
Only in Galen
Generates testable biological predictions using template-based reasoning, then immediately verifies them against independent experimental databases (ChEMBL, cBioPortal, and more). Each prediction is a hypothesis that can be confirmed or contradicted by real data — not an LLM opinion.
Parameters
Request Body
Compound and gene/target pair, with optional cancer type for tissue-specific predictions.
| Field | Type | Description |
|---|---|---|
compound | string | Drug or compound name (e.g. small molecule, antibody, or clinical-stage agent). |
gene | string | Gene or protein target to predict the drug's effect on. |
cancer_type | string | Optional cancer type for tissue-specific predictions (e.g. NSCLC, melanoma, AML). |
Response Schema
entitystringThe primary entity queried (compound or gene).entity_typestringType classification of the primary entity.predictionsarrayIndividual testable predictions with verification results.template_typestringType of prediction template used (e.g. drug_sensitivity, target_inhibition, synergy).hypothesisstringHuman-readable testable statement that can be confirmed or falsified.confidencefloatPrior confidence in this prediction (0.3–0.7) based on knowledge graph evidence.resultstring"confirmed", "contradicted", or "inconclusive" based on database verification.actual_valuestring | nullReal measurement from the verification database (e.g. IC50, effect size). Null if no data available.verification_dbstringDatabase used for verification (e.g. ChEMBL, cBioPortal).verification_time_msintegerTime taken to verify this individual prediction in milliseconds.confirmedintegerCount of predictions confirmed by experimental data.contradictedintegerCount of predictions contradicted by experimental data.inconclusiveintegerCount of predictions where no definitive experimental data was available.computation_time_msintegerTotal server-side computation time in milliseconds.Example Request
import requests
resp = requests.post(
"https://research.usegalen.com/api/v1/predictions/drug-response",
headers={"X-API-Key": "YOUR_API_KEY"},
json={
"compound": "erlotinib",
"gene": "EGFR",
"cancer_type": "NSCLC"
},
)
data = resp.json()
print(f"Confirmed: {data['confirmed']}, Contradicted: {data['contradicted']}")
for pred in data["predictions"]:
print(f" [{pred['result']}] {pred['hypothesis']}")
if pred["actual_value"]:
print(f" Evidence: {pred['actual_value']} ({pred['verification_db']})")Example Response
{
"entity": "erlotinib",
"entity_type": "compound",
"predictions": [
{
"template_type": "drug_sensitivity",
"hypothesis": "EGFR-mutant NSCLC cell lines show sensitivity to erlotinib (IC50 < 1 µM).",
"confidence": 0.65,
"result": "confirmed",
"actual_value": "IC50 = 0.038 µM (HCC827, EGFR del19)",
"verification_db": "ChEMBL",
"verification_time_ms": 312
},
{
"template_type": "target_inhibition",
"hypothesis": "Erlotinib inhibits EGFR kinase activity with nanomolar potency.",
"confidence": 0.62,
"result": "confirmed",
"actual_value": "Ki = 0.7 nM (EGFR wild-type kinase domain)",
"verification_db": "ChEMBL",
"verification_time_ms": 187
},
{
"template_type": "resistance_marker",
"hypothesis": "EGFR T790M mutation confers resistance to erlotinib in NSCLC.",
"confidence": 0.58,
"result": "confirmed",
"actual_value": "T790M detected in 49.3% of erlotinib-resistant cases (n=1,247 patients)",
"verification_db": "cBioPortal",
"verification_time_ms": 524
},
{
"template_type": "combination_synergy",
"hypothesis": "Erlotinib combined with MET inhibitor shows synergy in EGFR-mutant NSCLC.",
"confidence": 0.45,
"result": "inconclusive",
"actual_value": null,
"verification_db": "cBioPortal",
"verification_time_ms": 298
}
],
"confirmed": 3,
"contradicted": 0,
"inconclusive": 1,
"computation_time_ms": 1321
}Try It
Request Body
Compound and gene/target pair, with optional cancer type for tissue-specific predictions.
POST https://research.usegalen.com/api/v1/predictions/drug-responseRelated Endpoints